NeurologyLive® Friday 5 — July 26, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: MS Self-Management: What Does It Mean?

As part of our Summer digital edition, Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, explored 3 perspectives on self-managing multiple sclerosis (MS): a general consensus, insights from MS-Selfie, and a future technology-based model.

2: Altering Alzheimer Care Landscape With New, Advanced Therapeutics: Martin Tolar, MD, PhD

The president and CEO at Alzheon shared recent insights into neurodegenerative diseases that suggest a single toxic trigger may be responsible for conditions like Alzheimer disease, leading to potential early intervention and treatment strategies. [WATCH TIME: 10 minutes]

3: A Comprehensive Program to Enhance Inpatient Care for Patients With Parkinson Disease

Patricia Clark, CNP, a nurse practitioner at the Cleveland Clinic, talked about a specialized program for hospitalized patients with Parkinson disease that aligns hospital protocols with home medication regimens to improve care.

4: NeuroVoices: David Shprecher, DO, MSci, FAAN, on Current and Future Directions in Biomarker Testing for Atypical Parkinsonism

The director of movement disorders at the Banner Sun Health Research Institute talked about recent, promising advancements for diagnosing atypical Parkinsonian disorders and the questions that remain.

5: Real-World Data for Risdiplam in Adult Patients with Spinal Muscular Atrophy

In this Peer Exchange episode, panelists examine the available real-world data (RWD) on the use of risdiplam in adult patients with spinal muscular atrophy (SMA) from various studies conducted worldwide, discussing its potential efficacy and safety as a treatment option for adult SMA patients.